Journal
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
Volume 38, Issue 3, Pages 535-540Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1447-0756.2011.01743.x
Keywords
anticancer medication; berberine; ovarian cancer; OVCAR-3; SKOV-3
Categories
Funding
- Konkuk University
Ask authors/readers for more resources
Aim: The aim of this study is to analyze the impact of berberine on the two human epithelial ovarian carcinoma cell lines OVCAR-3 and SKOV-3 in relation to the potential usefulness of berberine in the treatment of epithelial ovarian cancer. Methods: Under adherent culture conditions, the cell lines were treated with berberine and analyzed for changes in cell growth. The cell cycle duration and degree of apoptosis were evaluated by means of propidium iodide staining and Annexin V staining. Results: After the berberine treatment, the two cell lines showed a dose-dependent reduction in the growth rate. In the cell cycle analysis, the OVCAR-3 and SKOV-3 cells showed an increased DNA content of 5% in the G2/M phase and 7% in the S phase, respectively. Additionally, the results confirm the cell cycle arrest by immunoblotting and the up-regulation of p27; however, in the apoptosis analysis, neither cell line showed an increase in apoptosis after the berberine treatment. Conclusion: Berberine treatment can inhibit proliferation through a cell cycle arrest in OVCAR-3 and SKOV-3 cells. Thus, berberine may be a novel anticancer drug for the treatment of ovarian cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available